fy17 msrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov.  pre-application and application deadlines will be available when the program announcements are released. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

exploration – hypothesis development award – preproposal due june 26

• independent investigators at or above the level of assistant professor (or equivalent)

·         all applications submitted in this funding opportunity must address one of the three focus areas described below: 

·         obstacles to remyelination and/or obstacles to axonal protection in ms

·         note: projects addressing the mechanisms of demyelination and neurodegeneration or secondary injury following inflammation will not be considered for funding.

·         biological correlates of disease activity and progression

·         studies may identify or validate markers using pre-existing bio-specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered studies. 

·         note:  acquisition of new specimens will not be supported.

·         the biology, measurement, or treatment of ms symptoms

·         symptoms may include: pain, fatigue, cognitive dysfunction, visual impairment, motor impairment, impaired mobility, loss of bladder control, sexual dysfunction, depression, and anxiety.

• note:  studies of disease-modifying or regenerative therapies that secondarily impact symptoms will not be considered for funding

·         pre-application submission is required; application submission is by invitation only.

·         supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the ms research field.

·         preliminary data are not required.

• clinical trials not allowed.

·         maximum funding of $150,000 for direct costs (plus indirect costs)

• maximum period of performance is 2 years

investigator-initiated research award – preproposal due june 26

• independent investigators at or above the level of assistant professor (or equivalent)

·         all applications submitted in this funding opportunity must address one of the two focus areas described below: 

·         obstacles to remyelination and/or obstacles to axonal protection in ms

·         note: projects addressing the mechanisms of demyelination and neurodegeneration or secondary injury following inflammation will not be considered for funding.

·         biological correlates of disease activity and progression

·         studies may identify or validate markers using pre-existing bio-specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered studies. 

• note: acquisition of new specimens will not be supported.

·         pre-application submission is required; application submission is by invitation only.

·         supports highly rigorous, high-impact research with the potential to make an important contribution to ms research and/or patient care.

·         preliminary data are required.

• clinical trials not allowed.

·         maximum funding of $600,000 for direct costs (plus indirect costs)

• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the msrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

professionals who have extensive operational or policymaking experience in civil registration systems, identification, electoral, and single registry programs, stemming from their experience in senior government positions or academia, and/or skills in one of the following six specialized areas are invited to register in the directory of experts:

• civil registration; statistics (including vital statistics data analysis);
• law;
• management of large operations;
• digitization (including it systems design, and system integration and interoperability); communication;
• social mobilization and behaviour change (including socio-cultural and anthropological research); and
• public health.

oicr has established the cancer therapeutics innovation pipeline (ctip) strategic initiative to capitalize on ontario’s expertise in cancer biology and drug discovery. ctip aims to support the translation of ontario discoveries into therapeutic assets with the potential for improving the lives of cancer patients.

to stimulate collaborative research with the ontario cancer research community in the area of cancer therapeutic discovery, oicr invites applications for early stage drug discovery. the announcement, request for applications and application registration form are attached. for more details, visit https://oicr.on.ca/funding-opportunities

timeline:

·         registration deadline: june 16, 2017

·         full application deadline: august 15, 2017

·         notification of award: october 16, 2017

·         funding to begin: december 2017

the healthy behaviour data challenge is expected to:

• identify and use creative new types of data and data sources to enhance public health surveillance of physical activity, sedentary behaviour and sleep.

for more information, please consult the healthy behaviour data challenge website.

the operating grant: hiv/aids community-based research is expected to:

• promote the creation of new knowledge that addresses gaps in the care cascade and reduces the incidence of new infections in high risk groups by focusing research on prevention efforts relevant to communities affected by hiv in canada and aligns with the goals of the federal initiative;
• promote the dissemination of new knowledge and uptake of evidence into action to enhance the community response to the hiv/aids epidemic;
• develop partnerships between researchers and affected communities;
• build capacity in the knowledge user community to engage in research and use evidence in their everyday business;
• build the next generation of hiv/aids cbr researchers through meaningful engagement of trainees in high quality cbr projects.

in the context of improved health for canadians, the objectives of collaborative health research projects (chrp) initiative are to:

• translate research results to knowledge/technology users and other stakeholders;
• encourage the natural sciences or engineering and health research communities to collaborate and integrate their expertise;
• advance interdisciplinary research leading to knowledge and technologies;
• benefit canada by improving the canadian healthcare system and/or services;
• lead to economic opportunities in canada (where appropriate); and
• provide training opportunities in collaborative and interdisciplinary research of relevance to health, while preparing them for employment opportunities in the private, public or not for profit sectors.

the catalyst grant: population health intervention research on the legalization and regulation of non-medical cannabis in canada is expected to:

• support the prompt initiation of intervention research that will assess how the legalization and regulation of non-medical cannabis in canada could directly or indirectly impact population health and health equity;
• generate data and evidence to monitor and evaluate the potential benefits, harms, and unintended consequences of legalizing and regulating non-medical cannabis to population health and health equity; and
• facilitate consideration and application of new evidence from population health intervention research to inform ongoing and future development of policies, practices, and programs involving cannabis.

the catalyst grant: hiv/aids community-based research funding opportunity is expected to:

• catalyze future applications for more comprehensive community-based research grants that focus on the development and/or implementation of interventions for the prevention of hiv and/or gaps in the care cascade.
• support partnerships between communities affected by hiv in canada and researchers to facilitate the conduct of community-based research.

fy17 vrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

clinical trial award – pre-application due july 12, full applications due october 25

principal investigators (pis) must be at or above the level of assistant professor (or equivalent).

preproposal is required; application submission is by invitation only.

·         supports research with the potential to have a major impact on the treatment or management of visual injury and/or dysfunction.

·         the proposed intervention to be tested should offer significant potential impact for military service members, veterans, and other individuals living with visual dysfunction.

·         funding from this award mechanism must support a clinical trial that is expected to begin no later than 12 months after the award date and should not be used for preclinical research studies. 

·         preliminary data supporting the proposed clinical trial are required.

·         funded studies will be required to file the study in the national institutes of health (nih) clinical trials registry, www.clinicaltrials.gov. 

• at the end of the period of performance, this work should show clear progress toward the next stage of implementation (i.e., phase ii clinical trials, u.s. food and drug administration clearance for a medical device, etc.).

·         maximum funding of $5.25m for total costs (direct and indirect costs)

• maximum period of performance is 4 year

technology and therapeutic development award - pre-application due july 12, full applications due october 25

pis who are independent investigators at any level are eligible to submit applications.

preproposal is required; application submission is by invitation only.

• supports the translation of promising preclinical findings into products for clinical applications, including detection, diagnosis, treatment, or quality of life.  products in development should be responsive to the healthcare needs of military service members, veterans, and other individuals living with visual dysfunction.
• the product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics), device, or a knowledge-based product.

• a “knowledge product” is a non-materiel product that addresses an identified need, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions (systems to develop, acquire, provide, and sustain medical solutions and capabilities), and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.  

·         the principal investigator (pi) must provide a transition plan showing how the product will progress to the next level of development after the completion of the vrp award.

·         proof-of-concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. 

• applications must include relevant data that support the rationale for the proposed study.  these data may be unpublished and/or from the published literature.

·         maximum funding of $2.1m for total costs (direct and indirect costs)

• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the vrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

fy17 lcrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

applications submitted to the fy17 lcrp must address at least one of the seven areas of emphasis listed below:

• identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.
• identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer.  screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.
• understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
• identify innovative strategies for prevention and treatment of early and/or localized lung cancer.
• understand predictive and prognostic markers to identify responders and nonresponders.
• understand susceptibility or resistance to treatment.
• understand contributors to lung cancer development other than tobacco.

military relevance:  the fy17 lcrp seeks to support research that is relevant to the healthcare needs of military service members, veterans, and their families.  military relevance will be considered in determining relevance to the mission of the dhp and fy17 lcrp during programmatic review.  investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

• use of military or veteran populations, biospecimens, data/databases, or programs in the proposed research.
• collaboration with department of defense or department of veterans affairs (va) investigators.
• involvement of military consultants (army, air force) or specialty leaders (navy, marine corps) to the surgeons general in a relevant specialty area.
• description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.
• explanation of how the project addresses an aspect of lung cancer that has direct relevance to military service members, veterans, or other military health system beneficiaries, including environmental exposures other than tobacco.

concept award – letter of intent due july 27

investigators at all academic levels

supports highly innovative, untested, potentially groundbreaking concepts in lung cancer

emphasis on innovation

clinical trials not allowed

preliminary data discouraged

military relevance strongly encouraged

maximum funding of $100,000 in direct costs (plus indirect costs)

period of performance should not exceed 1 year

career development award – letter of intent due september 13

principal investigator:  independent investigators at the level of assistant professor, instructor, or equivalent; must be within 5 years of first faculty appointment

mentor:  at or above the level of associate professor (or equivalent); have a proven publication and funding record in lung cancer research

supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher

clinical trials not allowed

preliminary data not required

military relevance strongly encouraged

maximum funding of $250,000 in direct costs (plus indirect costs)

period of performance should not exceed 2 years

idea development award – preproposal due june 28

established investigators:  independent investigators at or above the level of assistant professor (or equivalent); or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

have not previously received a lcrp idea development award or early investigator synergistic idea award

are within 10 years of first faculty appointment (or equivalent)

supports new ideas in the early stages of development representing innovative, high-risk/high-gain research

emphasis on innovation and impact

new investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers

clinical trials not allowed

preliminary data required, but may be from outside of lung cancer

military relevance strongly encouraged

maximum funding of $350,000 in direct costs (plus indirect costs)

period of performance should not exceed 2 years

investigator-initiated translational research award = preproposal due june 28

independent investigators at or above the level of assistant professor (or equivalent)

supports translational research that will develop promising ideas in lung cancer into clinical applications.  translational research may be defined as an integration of basic science and clinical observations

this mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:

studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts

late-stage preclinical work leading to/preparing for a clinical trial, e.g., investigational new drug submission

correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials

preliminary data required, but may be from outside of lung cancer

military relevance strongly encouraged

maximum funding of $400,000 in direct costs (plus indirect costs)

period of performance should not exceed 2 years

translational research partnership award – preproposal due june 28

investigators at or above the level of assistant professor (or equivalent)

supports partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications

one partner must be from either a military treatment facility or a va medical center

non-traditional partnerships are encouraged

small-scale clinical trials allowed

preliminary data required, but may be from outside of lung cancer

military relevance strongly encouraged

maximum combined funding of $900,000 for direct costs (plus indirect costs)

maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that are available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the lcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).